Extended Data Fig. 6: ELOVL6i treatment induces attenuation of oncogenic signaling and KRAS-driven tumor growth in a heterozygous G12V KRAS mutant SW403 colon cancer model.
From: ELOVL6 activity attenuation induces mutant KRAS degradation
a, Effect of ELOVL6i treatment (300 mg/kg) on tumor volume and body weight in SW403(KRASG12V/WT) xenografts (Vehicle: n = 8; ELOVL6i: n = 7). Two-way ANOVA with Tukey’s multiple comparisons test was used to determine statistical significance (P = 0.001). ***P < 0.001, data are represented as mean ± s.e.m. b, Western blotting analysis of the impact of ELOVL6i treatment on KRAS effector signaling pathways in SW403 tumors collected from mice (n = 3) after 3 weeks of treatment. c, Flow cytometry analysis of cell populations with high pERK expression in tumors collected after 3 days, 1 week, and 3 weeks post-ELOVL6i treatment. d, MFI of pERK expression level relative to vehicle treated samples at each timepoint from three biological replicates (P = 0.007; P = 0.019). Two-tailed unpaired T-test was used to determine statistical significance. *P < 0.05, **P < 0.01, data are represented as mean ± s.d.
